trial

Treatment of Refractory Schizophrenia With Riluzole

NCTId NCT00375050
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 34 (actual)
Sponsored by Yale University
Primary completion 2006-08-29
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
34 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2002-05
Primary completion
2006-08-29
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Riluzole

Sponsors

Yale UniversityLead Sponsor
Stanley Medical Research InstituteCollaborator

Investigators

1
Zoran Zimolo, MD, Ph.D.Principal Investigator

Sites

1 total
New Haven, United States

Facts & assertions

4 sourced
Enrollment
34
Phase
NA
Primary Completion Date
2006-08-29
Status
COMPLETED
relationships
The graph out of here
drug
Riluzole
drug
lead_sponsor
Yale University
company
collaborator
Stanley Medical Research Institute
company
indication
Schizophrenia
indication
Schizoaffective
indication
Schizophrenia
indication
investigator
Zoran Zimolo, MD, Ph.D.
person